What Is Sodium Butyrate Studied For? Research Areas, Per the Literature

The question "what is sodium butyrate used for" is best answered as what sodium butyrate has been studied for. The published record is dominated by cell culture work and rodent experiments, organised around a handful of research areas: intestinal inflammation, tumour cell biology, central nervous system injury and memory, liver fibrogenesis, acute kidney injury and the macrophage response to bacterial infection. Sodium Butyrate is not approved by the FDA as a medicine for any condition. This page is not guidance.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, medication or supplement. Each claim below names the study type and the model, and carries its PubMed link in the same passage.

What Sodium Butyrate Is, in Research Terms

Sodium butyrate is the sodium salt of butyric acid, a short-chain fatty acid. In the experimental literature it is most often handled as an epigenetic modifier. A 2019 rat study of neonatal hypoxia-ischemia described sodium butyrate explicitly as a histone deacetylase (HDAC) inhibitor and examined its relationship to neurogenesis (PMID 30767185). A separate line of work extends beyond acetylation: a 2025 study on liver fibrogenesis reported that sodium butyrate acted through promotion of H4K8 crotonylation, another histone modification (PMID 40180786). Other reports attribute effects to receptor signalling rather than chromatin, for example a rat stroke study that implicated the GPR41/G\u03b2\u03b3/PI3K/Akt pathway (PMID 32151222).

Background on the molecule itself is collected on the sodium butyrate learn page.

Research Areas at a Glance

Gut Inflammation and Colitis

Intestinal inflammation is the area most commonly associated with butyrate, because butyrate is produced in the colon by bacterial fermentation. A 2025 study in colitis models reported that sodium butyrate alleviated colitis by inhibiting mitochondrial reactive oxygen species that mediated macrophage pyroptosis (PMID 40044062). Researchers in that work framed the macrophage as the cell of interest rather than the epithelium, and the readouts were inflammatory cell death pathways rather than patient-reported outcomes.

Nothing in that report establishes an effect in people with ulcerative colitis or Crohn disease. The study is preclinical, and the conclusion stated in its title concerns a mechanism observed in a model system (PMID 40044062).

Cancer Cell Biology

Colorectal cancer models

Two reports address colorectal cancer directly. A 2024 study reported that sodium butyrate blocked the growth of colorectal cancer by inhibiting aerobic glycolysis mediated by SIRT4/HIF-1\u03b1, placing tumour metabolism at the centre of the mechanism (PMID 39241941). A 2025 study examined sodium butyrate alongside the kinase inhibitor sorafenib and reported enhanced ferroptosis and immunogenic cell death through modulation of the IRF2-Oasl2-cGAS pathway in colorectal cancer (PMID 41281652). Both are laboratory investigations of cancer cell behaviour, not clinical trials in patients.

Endometrial cancer cells

A 2023 in vitro study of endometrial cancer cells reported that sodium butyrate induced ferroptosis through the RBM3/SLC7A11 axis (PMID 37170022). SLC7A11 is a cystine transporter tied to glutathione synthesis, and ferroptosis is an iron-dependent form of regulated cell death; the study reported this as the route by which treated cells died.

Combination with cytotoxic agents

Older cell work examined sodium butyrate as a modifier of chemotherapy response. A 2016 report described sodium butyrate enhancing the antiproliferative effect of high concentrations of actinomycin D in cultured cells (PMID 30198696). That finding sits at the in vitro level and says nothing about outcomes in treated patients.

Across these four reports, the common thread is that researchers studied cancer cell lines and tumour models, and reported changes in proliferation, metabolism or regulated cell death (PMID 39241941, PMID 37170022). Preclinical antitumour activity frequently fails to reproduce in humans, and no human oncology outcome is established by this set of papers.

Brain, Behaviour and Memory

Fear extinction in a PTSD model

A 2021 rat study reported that sodium butyrate enhanced fear extinction and rescued hippocampal acetylcholinesterase activity in a model of posttraumatic stress disorder (PMID 33883448). The population was laboratory rats subjected to a stress paradigm, and the outcomes were behavioural extinction measures plus a hippocampal enzyme assay.

Memory

A 2021 paper in a learning and memory journal framed sodium butyrate as a selective cognitive enhancer for weak or impaired memory, a framing that implies the effect was conditional on baseline performance rather than general (PMID 33610771). This is preclinical cognition research; the paper does not report a trial in healthy adults or in people with cognitive impairment.

Stroke and neonatal brain injury

In a rat middle cerebral artery occlusion model of ischaemic stroke, researchers reported that sodium butyrate attenuated neuronal apoptosis via the GPR41/G\u03b2\u03b3/PI3K/Akt pathway (PMID 32151222). In a separate rat model of neonatal hypoxia-ischemia, a 2019 study examined the effect of sodium butyrate as an HDAC inhibitor on neurogenesis and proposed a mechanism of action (PMID 30767185). Both used acute injury models in rodents, which are a long distance from stroke care or neonatal intensive care practice.

Liver Fibrosis

A 2025 study reported that sodium butyrate attenuated liver fibrogenesis by promoting H4K8 crotonylation (PMID 40180786). Fibrogenesis refers to the deposition of scar tissue that follows chronic liver injury, and the study located the effect in a histone modification rather than in a conventional drug target. The evidence here is preclinical and single-report; no human liver outcome is demonstrated by it (PMID 40180786).

Kidney Injury

A 2022 study reported that sodium butyrate alleviated lipopolysaccharide-induced kidney injury by inhibiting TLR2/4 signalling to regulate rBD2 expression (PMID 35322444). Lipopolysaccharide challenge is a standard way to model endotoxin-driven inflammatory organ injury in animals. The study reported a signalling mechanism and an antimicrobial peptide readout, not clinical kidney function in patients.

Infection and Macrophage Responses

A 2019 study reported that sodium butyrate ameliorated Corynebacterium pseudotuberculosis infection in RAW264.7 macrophages and in C57BL/6 mice (PMID 30965088). The model combined a cultured macrophage cell line with an inbred mouse strain, and the organism studied is a veterinary pathogen rather than a common human infection. This work belongs to host-defence research and does not support any antimicrobial claim in people (PMID 30965088).

Where the Evidence Is Thin, Preclinical Only or Absent

Several topics commonly attached to the name sodium butyrate are not represented in the verified literature summarised here. Plainly stated:

• Human clinical trials. Every paper cited on this page is in vitro, in animals, or both, including the colitis (PMID 40044062) and stroke (PMID 32151222) reports. No controlled human outcome trial is included.
• Weight loss, body composition and metabolic endpoints. No paper in this set examined those outcomes; the metabolic work cited concerned tumour glycolysis in cancer models rather than whole-body metabolism (PMID 39241941).
• "Leaky gut" and barrier permeability in humans. The gut paper summarised here measured macrophage pyroptosis and mitochondrial ROS in a colitis model, not intestinal permeability in people (PMID 40044062).
• Psychiatric treatment. The behavioural evidence is a rodent fear-extinction model (PMID 33883448), which is a model of a process, not evidence of treatment effect in patients with posttraumatic stress disorder.
• Cognitive enhancement in healthy people. The cognition paper framed the effect as selective for weak or impaired memory in preclinical work (PMID 33610771), and no human cognitive trial appears in this set.

Safety and Adverse Events: What Studies Report

The verified papers summarised here were designed to test mechanisms in cells and animals, not to characterise human safety. Several reported cell death as the intended experimental outcome in tumour models, including ferroptosis in endometrial cancer cells (PMID 37170022) and enhanced antiproliferative activity when combined with actinomycin D in culture (PMID 30198696). Cytotoxicity directed at cancer cells in a dish is an experimental endpoint and is not a human tolerability profile. No human adverse-event dataset is presented in the studies cited on this page, and none of the animal reports summarised here, including the kidney injury study (PMID 35322444), substitutes for clinical safety data.

How to Read This Body of Work

Three limits apply across the research areas above. First, model distance: a rat middle cerebral artery occlusion is a controlled surgical injury, not a human stroke (PMID 32151222). Second, mechanism is not outcome: identifying H4K8 crotonylation as a route in fibrogenesis describes biology without demonstrating clinical benefit (PMID 40180786). Third, single reports are provisional: most areas on this page rest on one or two papers, such as the single macrophage and mouse infection study (PMID 30965088), and independent replication is what moves a finding forward.

Sodium Butyrate is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, medication or supplement.

References

• Sodium butyrate alleviates colitis by inhibiting mitochondrial ROS mediated macrophage pyroptosis (Biochimica et Biophysica Acta. Molecular Basis of Disease, 2025)
• Sodium butyrate blocks the growth of colorectal cancer by inhibiting the aerobic glycolysis mediated by SIRT4/HIF-1\u03b1 (Chemico-Biological Interactions, 2024)
• Sodium butyrate enhances sorafenib-induced ferroptosis and immunogenic cell death by modulating IRF2-Oasl2-cGAS pathway in colorectal cancer (Materials Today Bio, 2025)
• Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis (Apoptosis, 2023)
• Sodium butyrate enhances the antiproliferative effect of high concentrations of actinomycin D (Tsitologiia, 2016)
• Sodium butyrate enhances fear extinction and rescues hippocampal acetylcholinesterase activity in a rat model of posttraumatic stress disorder (Behavioural Pharmacology, 2021)
• Sodium butyrate as a selective cognitive enhancer for weak or impaired memory (Neurobiology of Learning and Memory, 2021)
• Sodium butyrate attenuated neuronal apoptosis via GPR41/G\u03b2\u03b3/PI3K/Akt pathway after MCAO in rats (Journal of Cerebral Blood Flow and Metabolism, 2021)
• Effect of the HDAC Inhibitor, Sodium Butyrate, on Neurogenesis in a Rat Model of Neonatal Hypoxia-Ischemia: Potential Mechanism of Action (Molecular Neurobiology, 2019)
• Sodium butyrate attenuates liver fibrogenesis via promoting H4K8 crotonylation (Molecular and Cellular Biochemistry, 2025)
• Sodium butyrate alleviates LPS-induced kidney injury via inhibiting TLR2/4 to regulate rBD2 expression (Journal of Food Biochemistry, 2022)
• Sodium butyrate ameliorates Corynebacterium pseudotuberculosis infection in RAW264.7 macrophages and C57BL/6 mice (Microbial Pathogenesis, 2019)